<< Study examines impact of managed care on stroke prevention surgery | Specialized kidney transporter improves transplant results >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | Русский

Study links MiR-29 molecule to muscle maturation, muscle cancer

Published on January 1, 2009 at 9:59 PM · No Comments

Researchers at The Ohio State University Comprehensive Cancer Center have discovered that a molecule implicated in leukemia and lung cancer is also important in muscle repair and in a muscle cancer that strikes mainly children.

The study shows that immature muscle cells require the molecule, called miR-29, to become mature, and that the molecule is nearly missing in cells from rhabdomyosarcoma, a cancer caused by the proliferation of immature muscle cells.

Cells from human rhabdomyosarcoma tumors showed levels of the molecule that were 10 percent or less of those in normal muscle cells. Artificially raising the level of the molecule in the cancer cells cut their growth by half and caused them to begin maturing, slowing down tumor growth.

MiR-29 is a type of microRNA, a family of molecules that helps regulate the proteins cells produce. Researchers say this study is unusual because it also sheds light on the how a microRNA itself is regulated.

"This study shows that there is a connection between this microRNA, muscle development and rhabdomyosarcoma," says principal investigator Denis C. Guttridge, associate professor of molecular virology, immunology and medical genetics and a researcher with Ohio State's human cancer genetics program.

"The findings should give us a better understanding of muscle repair and development, and of rhabdomyosarcoma, and could lead to new treatments for this and other muscle diseases," he says.

The study is published in a recent issue of the journal Cancer Cell.

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading